Cozint

Cozint Pharmaceuticals is a biopharmaceutical company focused on the commercialization of treatments for rare diseases, specifically Wilson's disease. As the U.S. subsidiary of Orphalan, the company manages the regulatory and commercial operations for Cuvrior (trientine tetrahydrochloride) in the United States. Cuvrior was approved by the FDA in 2022 as a copper-chelating agent for adult patients with stable Wilson's disease who are tolerant of penicillamine. Cozint's mission is to provide innovative therapeutic solutions for patients suffering from orphan diseases with high unmet needs. The company is headquartered in Chicago, Illinois, and works closely with its parent organization to expand access to specialized metabolic therapies.